RESUMEN

An antilipidemic effect of poseidonol was tested in 123 patients with ischemic heart disease, stable angina of effort (II-III functional class), 40 patients with secondary pyelonephritis and 40 patients with chronic hepatosis-hepatitis associated with chronic alcoholism or diabetes mellitus. The patients had also hyperlipidemia. A positive effect of poseidonol was established: cholesterol content fell by 25.4, 20.6 and 18.7%, respectively; triglycerides level decreased by 63, 42 and 21.4%, respectively; B-lipoproteins fell by 55.5, 36.9 and 13.1%, respectively. High density lipoproteins rose by 40.2, 27 and 69.9%, respectively. No adverse effects either on the liver or kidney functions were observed.

Asunto(s)

Hiperlipidemia Familiar Combinada/tratamiento farmacológico , Hipolipemiantes/uso terapéutico , Humanos , Hipolipemiantes/farmacología , Pruebas de Función Renal , Lipoproteínas/metabolismo , Pruebas de Función Hepática , Resultado del Tratamiento